AZNAstraZeneca PLC

$166.29

$145.5452 weeks$208.62

Price

$166.29+13%1Y

1M-1.2%1Y+13%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Top tier

9/10

Value56

Quality86

Momentum58

Growth59

Strongest Quality, weakest Value · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

AstraZeneca is a global, innovation-driven biopharmaceutical business with operations in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca has a legal entity based in Iran, AstraZeneca Pars Company (“AstraZeneca Pars”), which has no employees, and is owned by non-US Group companies. In July 2017, AstraZeneca Pars submitted regulatory applications to the Iranian Food and Drug Administration and subsequently received marketing authorizations for several products.

In the company’s own words · 20-F filed Feb 24, 2026 · SEC EDGAR

P/E (TTM)27.4

Market Cap$271.29B

1Y Return+13%

5Y Return+61%

AstraZeneca PLC (AZN) reported revenue of $30.7B in H2 2025 (quarter ended December 31, 2025), up 137% from the same quarter a year earlier. That came with a gross margin of 81% and net income of $4.86B (16% of revenue). For the full year FY2025, revenue was $58.7B (+8.6% year on year) and net income $10.2B.

Raw charts

7 series · TTM

As reported to the SEC, without any scoring.

Drug Manufacturers - General

Ranks #3 of 16 by Smart Score